Literature DB >> 12417044

The intraductal carcinoma component is a significant prognostic parameter in patients with invasive ductal carcinoma of the pancreas.

Hiroshi Kawahira1, Takahiro Hasebe, Taira Kinoshita, Satoshi Sasaki, Masaru Konishi, Toshio Nakagori, Kazuto Inoue, Tatsuya Oda, Shin-ichirou Takahashi, Takenori Ochiai, Atsushi Ochiai.   

Abstract

We have sometimes encountered invasive ductal carcinomas (IDCs) of the pancreas containing intraductal carcinoma components in the intra- and / or extra-tumor area. The purpose of this study was to investigate whether intraductal carcinoma components would be useful for predicting the outcome of IDC patients. Forty-seven surgically treated IDCs were examined, and all histological tumor sections were stained with Elastica to accurately confirm intraductal carcinoma components. Well-known clinicopathological parameters that exhibited a significant correlation in the univariate analyses for predicting disease-free survival (DFS) and overall survival (OS) were entered into the Cox proportional hazard multivariate analysis. Since the lowest P-value predicting DFS or OS periods was observed in IDCs with more than 10% intraductal carcinoma components and those with 10% or less intraductal carcinoma components (P = 0.028 and P = 0.019), we established the cutoff value of intraductal carcinoma components at 10%. In the multivariate analyses for DFS and OS, the presence of more than 10% intraductal carcinoma components showed a marginally significant increase in the hazard rate (HR) of tumor recurrence (P = 0.067) and significantly increased the HR of mortality (P = 0.040). The present study demonstrated that IDCs with more than 10% intraductal carcinoma components were associated with a significantly better patient outcome than those with 10% or less intraductal carcinoma components.

Entities:  

Mesh:

Year:  2002        PMID: 12417044      PMCID: PMC5926875          DOI: 10.1111/j.1349-7006.2002.tb01216.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  12 in total

1.  Intraductal mucin-hypersecreting neoplasms of the pancreas. A clinicopathologic study of eight patients.

Authors:  F Rickaert; M Cremer; J Devière; L Tavares; J P Lambilliotte; S Schröder; D Wurbs; G Klöppel
Journal:  Gastroenterology       Date:  1991-08       Impact factor: 22.682

Review 2.  Pancreatic carcinoma.

Authors:  A L Warshaw; C Fernández-del Castillo
Journal:  N Engl J Med       Date:  1992-02-13       Impact factor: 91.245

3.  Outcome after surgical resection of intraductal papillary and mucinous tumors of the pancreas.

Authors:  E Cuillerier; C Cellier; L Palazzo; J Devière; P Wind; F Rickaert; P H Cugnenc; M Cremer; J P Barbier
Journal:  Am J Gastroenterol       Date:  2000-02       Impact factor: 10.864

4.  Assessment of significance of proportions of intraductal and infiltrating tumor growth in ductal carcinoma of the breast.

Authors:  S G Silverberg; A R Chitale
Journal:  Cancer       Date:  1973-10       Impact factor: 6.860

5.  Intraductal oncocytic papillary neoplasms of the pancreas.

Authors:  N V Adsay; C F Adair; C S Heffess; D S Klimstra
Journal:  Am J Surg Pathol       Date:  1996-08       Impact factor: 6.394

6.  Intraductal papillary components in invasive ductal carcinoma of the pancreas are associated with long-term survival of patients.

Authors:  N Fukushima; M Sakamoto; K Mukai; Y Kanai; K Shimada; T Kosuge; S Hirohashi
Journal:  Hum Pathol       Date:  2001-08       Impact factor: 3.466

7.  Dpc-4 protein is expressed in virtually all human intraductal papillary mucinous neoplasms of the pancreas: comparison with conventional ductal adenocarcinomas.

Authors:  C A Iacobuzio-Donahue; D S Klimstra; N V Adsay; R E Wilentz; P Argani; T A Sohn; C J Yeo; J L Cameron; S E Kern; R H Hruban
Journal:  Am J Pathol       Date:  2000-09       Impact factor: 4.307

8.  Molecular analysis of microdissected tumors and preneoplastic intraductal lesions in pancreatic carcinoma.

Authors:  E Heinmöller; W Dietmaier; H Zirngibl; P Heinmöller; W Scaringe; K W Jauch; F Hofstädter; J Rüschoff
Journal:  Am J Pathol       Date:  2000-07       Impact factor: 4.307

9.  Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors.

Authors:  K C Conlon; D S Klimstra; M F Brennan
Journal:  Ann Surg       Date:  1996-03       Impact factor: 12.969

10.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1977-01       Impact factor: 7.640

View more
  1 in total

1.  Pathological complete response (pCR) with or without the residual intraductal carcinoma component following preoperative treatment for pancreatic cancer: Revisiting the definition of "pCR" from the prognostic standpoint.

Authors:  Daisaku Yamada; Hidenori Takahashi; Kei Asukai; Shinichiro Hasegawa; Akira Tomokuni; Hiroshi Wada; Hirofumi Akita; Masayohi Yasui; Hiroshi Miyata; Osamu Ishikawa
Journal:  Ann Gastroenterol Surg       Date:  2019-09-20
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.